ReviewBioEssays : news and reviews in molecular, cellular and developmental biology2016
Enhancer deregulation in cancer and other diseases.
Review in BioEssays : news and reviews in molecular, cellular and developmental biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 120 citations in OpenAlex.
- Multi-omics Approaches to CCAAT/Enhancer-Binding Protein Beta in Oral Squamous Cell Carcinoma: Crosstalk Between Tumor Cells and Tumor-Associated Macrophages Driving Disease Progression.Current cancer drug targets · 2026Article
- Cell reprogramming in cancer: Interplay of genetic, epigenetic mechanisms, and the tumor microenvironment in carcinogenesis and metastasis.World journal of clinical oncology · 2025Review
- AttnW2V-Enhancer: Leveraging attention and Word2Vec for enhanced enhancer prediction.Computational and structural biotechnology journal · 2025Article
- Whole-Exome Analysis and Osteosarcoma: A Game Still Open.International journal of molecular sciences · 2024Review
- Oncogenic Enhancers in Leukemia.Blood cancer discovery · 2024Review
- Enhancer selectivity in space and time: from enhancer-promoter interactions to promoter activation.Nature reviews. Molecular cell biology · 2024Review
- Hidden secrets of the cancer genome: unlocking the impact of non-coding mutations in gene regulatory elements.Cellular and molecular life sciences : CMLS · 2024Review
- SomaticJournal of thoracic disease · 2024Article
- The Application of Long-Read Sequencing to Cancer.Cancers · 2024Review
- Enhancer-MDLF: a novel deep learning framework for identifying cell-specific enhancers.Briefings in bioinformatics · 2024Article
- Enhancer Recognition: A Transformer Encoder-Based Method with WGAN-GP for Data Augmentation.International journal of molecular sciences · 2023Article
- From Genotype to Phenotype: How Enhancers Control Gene Expression and Cell Identity in Hematopoiesis.HemaSphere · 2023Review
- Identification of a RAD51B enhancer variant for susceptibility and progression to glioma.Cancer cell international · 2023Article
- Article
- Epigenetic moonlighting: Catalytic-independent functions of histone modifiers in regulating transcription.Science advances · 2023Review
- iEnhancer-ELM: improve enhancer identification by extracting position-related multiscale contextual information based on enhancer language models.Bioinformatics advances · 2023Article
- Efficient Selection of Enhancers and Promoters from MIA PaCa-2 Pancreatic Cancer Cells by ChIP-lentiMPRA.International journal of molecular sciences · 2022Article
- iEnhancer-DCLA: using the original sequence to identify enhancers and their strength based on a deep learning framework.BMC bioinformatics · 2022Article
- The MLL3/4 complexes and MiDAC co-regulate H4K20ac to control a specific gene expression program.Life science alliance · 2022Article
- A machine learning technique for identifying DNA enhancer regions utilizing CIS-regulatory element patterns.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Mutations in enhancer-associated chromatin-modifying components and genomic alterations in non-coding regions of the genome occur frequently in cancer, and other diseases pointing to the importance of enhancer fidelity to ensure proper tissue homeostasis. In this review, I will use specific examples to discuss how mutations in chromatin-modifying factors might affect enhancer activity of disease-relevant genes. I will then consider direct evidence from single nucleotide polymorphisms, small insertions, or deletions but also larger genomic rearrangements such as duplications, deletions, translocations, and inversions of specific enhancers to demonstrate how they have the ability to impact enhancer activity of disease genes including oncogenes and tumor suppressor genes. Considering that the scientific community only fairly recently has begun to focus its attention on "enhancer malfunction" in disease, I propose that multiple new enhancer-regulated and disease-relevant processes will be uncovered in the near future that will constitute the mechanistic basis for novel therapeutic avenues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.